| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/16/2007 | US7163703 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 01/16/2007 | US7163685 DNA encoding one or more human cytomegalovirus proteins selected from pp65, pp150, IE1, gB and antigenic fragments |
| 01/16/2007 | US7163683 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen |
| 01/16/2007 | US7163682 For inducing antibody production against Streptococcal antigens |
| 01/16/2007 | US7163681 Isolated monoclonal antibody comprising a light and heavy chain variable of given sequence; diagnosing, treating and preventing prostate/colon cancer and renal carcinoma |
| 01/16/2007 | US7163680 Contacting vascular endothelial cells proximate to cancerous cells with the biological agent to permit both binding of biological agent to vascular endothelial cells proximate to cancerous cells and ablating or killing of cancerous cells |
| 01/16/2007 | US7163678 Lysis of proliferating cells; antitumor, antimetastasis, anticarcinogenic, and antiproliferative agents; genetic engineering |
| 01/16/2007 | CA2293682C Stable particle in liquid formulations |
| 01/16/2007 | CA2263911C Treatment of autoimmune diseases |
| 01/16/2007 | CA2168963C Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases |
| 01/11/2007 | WO2007006052A2 Malaria msp-1 c-terminal enhanced subunit vaccine |
| 01/11/2007 | WO2007006041A2 Imaging and therapeutic method using monocytes |
| 01/11/2007 | WO2007005955A2 Anti-il-23 antibodies, compositions, methods and uses |
| 01/11/2007 | WO2007005934A2 Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| 01/11/2007 | WO2007005898A2 Blocking leukocyte emigration and inflammation by interfering with cd99l2 |
| 01/11/2007 | WO2007005786A2 Methods and compositions with enhanced therapeutic activity |
| 01/11/2007 | WO2007005715A2 Staphylococcal antibodies which cross-react with fungal antigens |
| 01/11/2007 | WO2007005627A2 Tuberculosis antigen detection assays and vaccines |
| 01/11/2007 | WO2007005605A2 Phosphospecific chemokine receptor antibodies |
| 01/11/2007 | WO2007005502A2 Methods and compositions for treating diseases targeting cdcp1 |
| 01/11/2007 | WO2007005389A1 F11 receptor (f11r) antagonists as therapeutic agents |
| 01/11/2007 | WO2007005358A2 Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
| 01/11/2007 | WO2007005244A1 Henipavirus receptor and uses thereof |
| 01/11/2007 | WO2007005144A2 Improved allergen-specific immunotherapy |
| 01/11/2007 | WO2007004692A1 Prophylactic/therapeutic agent and diagnostic agent for non-small cell lung cancer |
| 01/11/2007 | WO2007004231A1 Hiv-1 vaccinogens with immunomodulators |
| 01/11/2007 | WO2007003936A1 Stable aqueous systems comprising proteins |
| 01/11/2007 | WO2007003904A2 Prophylactic and immunomodulatory compositions and uses |
| 01/11/2007 | WO2007003898A1 Process for attaching effector molecules to proteins |
| 01/11/2007 | WO2007003609A1 Treatment of liver cirrhosis and its complications |
| 01/11/2007 | WO2007003426A1 Anti-ccr7 receptor antibodies for the treatment of cancer |
| 01/11/2007 | WO2007003384A1 Anti-malaria vaccine |
| 01/11/2007 | WO2007003216A1 Anti-ccr7 receptor antibodies for the treatment of cancer |
| 01/11/2007 | WO2007003090A1 A composition instead of positive sera used as control in diagnostic agent and its application |
| 01/11/2007 | WO2007003010A1 Anticoagulation agent and uses thereof |
| 01/11/2007 | WO2006116950A3 A composition, its preparation method and its use |
| 01/11/2007 | WO2006113792A8 Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
| 01/11/2007 | WO2006110589A3 Gammaretrovirus associated with cancer |
| 01/11/2007 | WO2006108070A3 Inhibition of p-glycoprotein using act modulators and uic2 monoclonal antibody |
| 01/11/2007 | WO2006107945A3 Use of rip in treating staphylococcus aureus infections |
| 01/11/2007 | WO2006105062A3 Altered antibody fc regions and uses thereof |
| 01/11/2007 | WO2006100089A3 Identification of surface-associated antigens for tumor diagnosis and therapy |
| 01/11/2007 | WO2006094269A3 Anti-angiogenic compounds |
| 01/11/2007 | WO2006089114A3 Methods and compositions for treating an anthrax toxin mediated condition |
| 01/11/2007 | WO2006083936A3 Anti-ephb2 antibodies and methods using same |
| 01/11/2007 | WO2006083355A3 Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| 01/11/2007 | WO2006083322A3 Methods for the treatment and prevention of infection using anti-selectin agents |
| 01/11/2007 | WO2006082313A3 T cd4+ epitopes of type i and ii latency antigens of the epstein-barr virus, which can be recognised by the majority of individuals in the caucasian population and applications thereof |
| 01/11/2007 | WO2006063164A3 Compositions and methods for treating neuroendocrine tumors |
| 01/11/2007 | WO2006061259A3 Cytotoxic agents comprising new c-2 modified taxanes |
| 01/11/2007 | WO2005124358A3 Diagnosis and treatment of siglec-6 associated diseases |
| 01/11/2007 | WO2003083057A3 Adipocytes and uses thereof |
| 01/11/2007 | US20070011753 Method of producing a mouse suitable for engraftment, differentiation and proliferation of heterologous cells, mouse produced by this method and use of the mouse |
| 01/11/2007 | US20070010577 Administering an emulsion of a nanoparticulate carrier containing an alpha v beta 3 integrin targeting ligand and fumagillin, TNP 470 or rapamycin that are coupled through colocalization in the nanoparticles; the antiangiogenic agent is effective at a dosage at least 56,000 fold lower than the free drug |
| 01/11/2007 | US20070010471 HIV DNA vaccine |
| 01/11/2007 | US20070010470 Immunomodulatory oligonucleotides |
| 01/11/2007 | US20070010469 diagnosing colorectal cancer indicated by at least a two-fold increase in the amount of duplex formed from the patient sample as compared to the amount of duplex formed from the normal control |
| 01/11/2007 | US20070010468 Methods and compositions for the inhibition of stat5 in prostate cancer cells |
| 01/11/2007 | US20070010434 Novel compositions and methods for the treatment of immune related diseases |
| 01/11/2007 | US20070009994 Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen |
| 01/11/2007 | US20070009986 Compositions for modulating immune cell activity and methods for detection thereof |
| 01/11/2007 | US20070009971 for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 01/11/2007 | US20070009951 Gene expression vaccine |
| 01/11/2007 | US20070009892 Method of preparing epitopes chimeric gene vaccine |
| 01/11/2007 | US20070009602 Direct drug delivery system based on thermally responsive biopolymers |
| 01/11/2007 | US20070009597 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 01/11/2007 | US20070009569 Delivery device for topical, oral, intravenous, intraperitoneal, intramuscular, transdermal, nasal, or iontophoretic administration coated with a RNAIII inhibiting heptapeptide of the sequence Tyr-X2-Pro-X1-Thr-Asn-Phe where X1 is Cys, Trp or Ile, and X2 is Lys or Ser; antibiotic resistance |
| 01/11/2007 | US20070009556 Live genetically attenuated malaria vaccine |
| 01/11/2007 | US20070009555 Botulinum toxin and the treatment of primary disorders of mood and affect |
| 01/11/2007 | US20070009554 Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| 01/11/2007 | US20070009553 Bacterial strains of genus exiguobacterium, culture method and uses |
| 01/11/2007 | US20070009552 Simultaneous protection against each of the four dengue viruses, thereby precluding the possibility of developing the more serious illnesses dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), which occur in humans during secondary infection with a heterotypic wild-type dengue virus |
| 01/11/2007 | US20070009551 Aids ancestral viruses and vaccines |
| 01/11/2007 | US20070009550 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 01/11/2007 | US20070009549 Nucleic acid encoding envelope proteins from a donor with non-progressive HIV-1 infection |
| 01/11/2007 | US20070009548 Inactivated chimeric and related methods of use |
| 01/11/2007 | US20070009547 Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG |
| 01/11/2007 | US20070009546 Isolated nucleic acid; screening for antibacterial compounds |
| 01/11/2007 | US20070009545 For combating the pathogenic effects of Mycoplasma infection in an animal by administering an effective amount of isolated and purified mycoplasmal L-alpha-glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier |
| 01/11/2007 | US20070009544 Anti-allergic complex molecules |
| 01/11/2007 | US20070009543 Protein involved in ovarian cancer |
| 01/11/2007 | US20070009542 Method and device for transdermal immunization |
| 01/11/2007 | US20070009541 Drug conjugate composition |
| 01/11/2007 | US20070009540 Drug conjugate composition |
| 01/11/2007 | US20070009539 a liquid and/or lyophilized mixture of buffers and humanized antibody that binds tumor antigens, chemically coupled to a maytansine derivative, used as antitumor and/or anticarcinogenic agents |
| 01/11/2007 | US20070009538 Expression and export of angiogenesis inhibitors as immunofusins |
| 01/11/2007 | US20070009537 Antimicrobial activity of antibodies producing reactive oxygen species |
| 01/11/2007 | US20070009536 Novel MAdCAM antibodies |
| 01/11/2007 | US20070009535 Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
| 01/11/2007 | US20070009534 Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
| 01/11/2007 | US20070009533 Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
| 01/11/2007 | US20070009532 Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
| 01/11/2007 | US20070009531 Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
| 01/11/2007 | US20070009530 Antitumor agents; antiproliferative agents; neurodegenerative diseases; using interfering rna; antagonist hedgehog gene; blocking antibodies |
| 01/11/2007 | US20070009529 Agents that dissolve arterial thrombi |
| 01/11/2007 | US20070009528 Antibodies to masp-2 |
| 01/11/2007 | US20070009527 Method for cloning of variable domain sequences |
| 01/11/2007 | US20070009526 Anti-IL-23 antibodies, compositions, methods and uses |
| 01/11/2007 | US20070009525 Human Endokine Alpha and Methods of Use |
| 01/11/2007 | US20070009524 Methods of treating inflammation associated with viral infection with anti-tnf antibodies |